Clinical trialNCT01352715CompletedPhase 3Interventional

Study of Options for Second-Line Effective Combination Therapy (SELECT)

SponsorAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsEnrollment515HIV-1 Infection

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The study was conducted on people who were taking their first anti-HIV drug regimen (including an Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), a type of anti-HIV drug) but the drugs in this regimen were not doing a good job of fighting their HIV infection. The main purpose of this study was to compare two other anti-HIV drug regimens to see how well they fight HIV. The study also looked at how well participants tolerate the drug regimens and how safe they are. The study was designed to determine whether taking the combination of lopinavir/ritonavir (LPV/r) plus raltegravir (RAL) works as well as what is usually used for second-line therapy: LPV/r plus the best-available nucleoside (nucleotide) reverse transcriptase inhibitor (NRTI) combination. Testing a regimen that does not include any NRTIs was important because NRTIs may no longer work for patients who received them as part of their first treatment regimen.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Alberto M La Rosa, MD
Asociacion Civil Impacta Salud y Educacion - Miraflores, CRS
Study Chair
clinicaltrials.gov ↗
Ann C Collier, MD
Univ. of Washington Clinical HIV Research Program (CHIRP)
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

16 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Brazil

Instituto de Pesquisa Clinica Evandro Chagas (12101)
Rio de Janeiro, Brazil

India

Bj Medical College Crs (31441)
Pune, Maharashtra, India
Nari Pune Crs
Pune, Maharashtra, India
Y.R.G Ctr, for Aids Research and Education (11701)
Chennai, India

Kenya

Ampath at Moi Univ. Teaching Hosp. Eldoret Crs (12601)
Eldoret, Kenya

Malawi

College of Med. Jhu Crs (30301)
Blantyre, Malawi
University of North Carolina Lilongwe Crs (12001)
Lilongwe, Malawi

Peru

San Miguel Crs
San Miguel, Lima region, Peru
Barranco Crs (11301)
Lima, Peru

South Africa

Wits Hiv Crs (11101)
Johannesburg, Gauteng, South Africa
Durban Adult Hiv Crs (11201)
Durban, South Africa
Soweto Actg Crs (12301)
Johannesburg, South Africa
Univ. of Witwatersrand Crs (11101)
Johannesburg, South Africa

Tanzania

Kilimanjaro Christian Medical Crs
Kilimanjaro Region, Moshi, Tanzania

Thailand

Chiang Mai University Actg Crs (11501)
Chiang Mai, Thailand

Zimbabwe

Uz-Parirenyatwa Crs (30313)
Harare, Zimbabwe

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Abacavir →Abacavir / lamivudineAbacavir / lamivudine / zidovudine →Emtricitabine →Lamivudine →Lopinavir →Raltegravir →Zidovudine →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 13 Mar 2012
Primary completion: 29 Oct 2014
Completion: 29 Oct 2014
Last update posted: 5 Aug 2021
Registered enrollment: 515
Registry id: NCT01352715

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.